Overview

The Trial of SHR6508 in Secondary Hyperparathyroidism

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.
Treatments:
Cinacalcet